Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...
Zacks Investment Research on MSN9d
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug FilingAxsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 ...
Auvelity is the first drug Axsome has taken through to regulatory approval, but could be the first of a string of new products for the company, according to Tabuteau. Next up is AXS-07 (meloxicam ...
Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted, or on or after Sept. 30, 2038, if no pediatric ...
Axsome Therapeutics' Q4 revenue surged to $118.77 million, surpassing expectations with significant growth in Auvelity sales. Axsome reports progress on multiple drug applications, including ...
Despite Auvelity's revenue growth ... that are notoriously difficult for drugs to prove safe and effective (high placebo rates, subjective patient-reported outcomes) in clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback